Skip to main content
. 2019 Feb 4;9(2):17. doi: 10.1038/s41408-019-0178-8

Fig. 1. Best percent change in either serum M-protein or serum free light chain levels (in patients without detectable M-protein) relative to baseline for all efficacy-evaluable patients.

Fig. 1

Two efficacy-evaluable patients are not depicted due to lack of detectable M protein or serum free light chains at baseline; both of these patients had a best response of progressive disease